



WAKE

March 2022



DISCLAIMER

This presentation of Wake Network, Inc. (“**Wake**” or the “**Company**”) is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. Neither this presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and the Company does not accept liability to any person in relation thereto.

Cautionary Note to United States Investors

This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of securities of the Company in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities of the Company described herein have not been and will not be registered under the United States federal or state securities laws and may not be offered or sold in the United States, or to, or for the account or benefit of, “U.S. Persons” as such term is defined in Regulation S under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), unless an exemption from registration is available. Prospective investors will be required to represent, among other things, that they meet the definition of “accredited investor” (as defined in Rule 501(a) of the U.S. Securities Act) and are familiar with and understand the terms of the offering and have all requisite authority to make such investment. Securities sold in the United States will be “restricted securities” within the meaning of Rule 144 under the U.S. Securities Act. The securities may be resold, pledged or otherwise transferred only pursuant to an effective registration statement under the U.S. Securities Act or pursuant to an applicable exemption from the registration requirements of the U.S. Securities Act.

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE OR CANADIAN SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING PASSED ON THE ACCURACY OR ADEQUACY OF THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

Forward-looking statements

This presentation contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance or achievements that the Company anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. In some cases, forward-looking information is identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “will”, “would”, and similar terms and phrases, including references to assumptions. Such information may involve, but is not limited to, comments with respect to strategies, expectations, planned operations or future actions. These forward-looking statements are based on currently available competitive, financial and economic data and operating plans as of the date of this presentation but are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements or industry results to be materially different from those expressed or implied by such forward- looking information. Such factors are based on information currently available to the Company, including information obtained from third-party industry analysts and other third party sources, and are based on management’s current expectations regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures. The forward-looking information contained in this presentation is expressly qualified by this cautionary statement.

A number of risks, uncertainties and other factors could cause actual results to differ materially from the results discussed in the forward-looking information, including, but not limited to, the following: legislative and regulatory developments; unfavourable results of research; new product development; product demand and market acceptance; the development of supplier and customer relationships; risks associated with the development of projects; risks associated with reliance on key personnel; control of costs and expenses including inability to fund capital expenditures and research and development; lack of cash flow; reliance on financing; general industry and market conditions and growth rates; general economic conditions and levels of economic activity including interest rate and currency exchange rate fluctuation; current global financial conditions; failure to realize on growth initiatives; degree of competition in the industry; and changes in employee relations.

Forward-looking information reflects the Company’s current beliefs and is based on information currently available to the Company and on assumptions it believes to be reasonable. In some instances, material factors or assumptions are discussed in this presentation in connection with statements containing forward-looking information. Such material factors and assumptions include, but are not limited to: the Company’s ability to execute on its business plan; the acceptance of the Company’s products and services by its customers, including renewals; the timing of execution of outstanding or potential customer contracts by the Company; the sales opportunities available to the Company; the Company’s subjective assessment of the likelihood of success of a sales lead or opportunity; that sales will be completed at or above the Company’s estimated margins; availability of government subsidies; the continued success of business development activities; new products and services will continue to be added to the Company’s portfolio; the demand for our products and services globally will develop and grow; to the extent needed, that additional financing is available.] The forward-looking information is made as of the date of this presentation and the Company assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law. Because of the risks, uncertainties and assumptions contained herein, prospective investors should not read forward-looking information as guarantees of future performance or results and should not place undue reliance on forward-looking information. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future.

Cautionary note regarding future-oriented financial information

To the extent any forward-looking statement in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Forward-looking Statements”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses.

Confidentiality

This presentation contains highly confidential information regarding the investments, strategy and organization of the Company. Your acceptance of this document constitutes your agreement to (i) keep confidential all the information contained in this document, as well as any information derived by you from the information contained in this document (collectively, the “**Confidential Information**”) and not disclose any such Confidential Information to any other person, (ii) not use any of the Confidential Information for any purpose other than to evaluate an investment into the Company, (iii) not copy this document without the Company’s prior consent, and (iv) promptly return this document and any copies hereof to the Company upon the Company’s request.

When everything opened up, into a better world. To show me *the real world*, it was a different life. For the first time in many years I haven't said, 'I hate myself'

-Scott




SCOTT & DAWN
Canadian Military Veteran
Caregiver
PTSD + Anxiety, Depression
Ottawa, Canada
Wake Clinic Patients 2020




WAKE

Wake is developing integrative psychedelic experiences by combining breakthrough research on human genetics, natural psilocybin, and traditional healing methods.




THE WAKE APPROACH

An integrated platform approach using deep data for precision and personalized psychedelic experiences.



KEY MILESTONES TO DATE

Since company formation in 'Q4 2019, Wake has continued to build critical infrastructure while advancing regulatory and research initiatives.



WHY INVEST IN WAKE?

Breakthrough Genetics Project

- Collaboration with leading brain and research institute to develop advanced screening service.
- Estimated 24 months to revenue.

Psilocybin Production

- Near term projection of revenue from psilocybin mushroom production from Jamaica.
- Numerous purchase agreement inquiries.
- Opportunities for sales to local Jamaica market.

World's 1st Legal Microdose Rx

- PSIL428 microdose drug (federally registered and approved).
- Local pharmacy sales in 2022 (est.)
- Opportunity for international export under pharmaceutical drug access programs.

Import / Export Complete

- First psilocybin mushroom importation into the United States with permitting from the Drug Enforcement Administration (DEA).
- Canadian import complete.

Psilocybin Drug Advancement

- Naturally derived psilocybin API (global) and drug formulations - DMF
- Microdose and macrodose formulation and delivery.
- Nootropic stacks for microdosing and post macrodosing therapeutics.

Management Expertise

- Mission-driven team.
- Operational understanding and experience.
- Disciplined approach to capital deployment.

THE MARKET WE ARE TARGETING


Psychedelic Drug
Market to reach **\$10.75
Billion** by 2027. CAGR
16.3% over the next 8
years. ¹

Digital Health
Market CAGR 15.1%
to 2028 and **\$96.5
Billion** in 2020.³

Globally, an
estimated **5%** of
adults suffer from
depression.⁵

Global Health and
Wellness industry
valued at **\$4.5
Trillion** in 2020.²

Approximately **284
Million** people suffer
from anxiety
globally, **only 36%**
seek treatment.⁴



¹Research and Markets, Psychedelics Drugs Market - Global Forecast to 2026

²Global Wellness Summit, The Future Of Wellness 2020


³Grandview Research Report on Global Digital Health Market

⁴Fortune Business Insights, Anxiety and Depression Market

⁵World Health Organization

OUR POSITIONING

- First to market with psilocybin mushroom microdose Rx product.
- Near term psilocybin mushroom biomass and Psil428 Rx revenue.
- Development of precision genetic screening and dosing IP is expected to be a key differentiator (medical device approval path).
- Experienced fungi and psilocybin producer.
- Proven track record of operational success.



OUR ADVISORY BOARD



BARI WILLIAMS ESQ.  
Tech Executive, Attorney, Diversity Activist
Lead Sr. Council at Facebook, Head of Business Operations
at Stubhub,



RYAN CUMMINS 
Philanthropy and Research
Co-Founded and scaled Omaze to raising hundreds of millions
for charity.



ADRIAN GRENIER 
Advocate, Actor
Co-Founder and Partner DuCONTRA Ventures
UN Regional Ambassador



ANDRE FERNANDEZ  
Operations
Former COO of Canopy Growth, leading all international operations.



PATRICK WILLIS
Athlete
San Francisco 49ers, NFL



RILEY COTE
Athlete and Psychedelic Integration
Philadelphia Flyers, NHL



SHILPA RAJGOPAL  
Marketing and Awareness
Director Retention Marketing at HIMS & HERS



EBEN BRITTON
Athlete and Psychedelic Integration
Chicago Bears, NFL

SENIOR LEADERSHIP



NICK MURRAY

CEO / Co-Founder, Director

Nick has been building security, health and technology companies for over 20 years. He was the founder of MobSafety (Moseda Technologies) and oversaw its growth from foundation through to IPO.

Moseda was the best performing stock on the TSX-V in 2015



PAULINE 'TERRI' SMITH

Chief Cultivation Officer & CEO Wake Jamaica

Founder of the Association of Mushroom Producers Limited and co-owner of the Jamaica Exotic Mushroom Farm. She founded the Network of Women for Food Security in 2010.

Terri is an accomplished keynote speaker, social entrepreneur and a craft mushroom grower



DAVID HACKETT

Chief Financial Officer, CA, CPA

David has over 25 years of public company experience as a Chief Financial Officer and most recently was CFO of 48North Cannabis where he led the IPO, raised over \$60 Million and grew revenue from \$0-\$30m in 3 years. He also has held positions at public companies on the Nasdaq, TSX and CSE.



ARAM HUMPART ZOOMIAN

Chief Technology Officer

15 years as head of software development for Wirecard fintech and payments platform. Experienced full stack development, hardware engineering, cryptography.



WARREN NEEDLER

President

Director of Giftagram, LaCure Private Hotels, Tequila Tromba, Principal at Foxgate Capital
Over 15 Years of Venture Capital Investing and entrepreneurship in technology, CPG, wine & spirits, cannabis and entertainment.



DR. OLGA CHERNOLOZ

Chief Scientific Officer, Director

PhD Neuroscientist, Pharmacist, Professor of Psychiatry, University of Toronto. 10+ years experience in pre-clinical and clinical research, and biotech project management.

Specialize in psychopharmacology, neuroscience and applied cannabinoid research.



DR. AUDIA BARNETT

Chief Operating Officer Wake Jamaica

Audia has over 20 years experience in legislative and government affairs in the Caribbean. She spent 9 years leading the IICA Agricultural initiative for Jamaica, as well as served as the Executive Director of the Scientific Research Council for the Government of Jamaica.



TYLER MACLEOD

Chief Experience Officer / Co-Founder

Hosted and curated experiences for health, wellness and entrepreneurial leaders globally, including Richard Branson at Necker Island, Ulusaba South African Wildlife Refuge & Virgin Galactic



OUR EXTENSIVE RESEARCH PARTNERS



DR. PETER CHARLES

Neurosurgeon, University Hospital of WI, Private Wing

Dr. Peter Charles is currently a consultant neurosurgeon at the University Hospital of the West Indies and an Associate Lecturer in the Department of Surgery at University of the West Indies (UWI), Mona



DR. JACOB PELLINEN

University of Colorado Medicine, Neurology*

Primary research interest is identifying factors that delay the diagnosis and treatment of patients with new-onset epilepsy, specifically identifying areas for potential intervention that could ultimately improve the quality of care for people with epilepsy



University of Colorado Medicine



DR. ROGER GIBSON

Professor Department of Psychiatry, Faculty of Medical Sciences

Dr. Roger Gibson holds the Bachelor of Medicine, Bachelor of Surgery from The University of the West Indies, Masters of Public Health with Distinction from the University of Leeds and the Doctor of Medicine



DR. MONNICA WILLIAMS

Canada Research Chair in Mental Health Disparities*

Dr. Williams work focuses on ethnic minority mental health and psychopathology research. She completed her undergraduate studies at MIT and UCLA and received her doctoral degree from the University of Virginia.



uOttawa



DR. WAYNE MCLAUGHLIN

Prof. Plant Molecular Biology, University Of West Indies

Dr. McLaughlin is the Head of Biochemistry at the University of West Indies and oversees projects ranging from genetic characterization, evolution to molecular biology and DNA fingerprinting.



DR. KYLE GREENWAY

Psychologist / Psychoanalyst*

Novel imaging techniques, clinical risk factors and cognitive changes associated with suicide, and novel psychiatric treatments including ketamine infusions for various disorders such as treatment-resistant depression.



DR. RYAN GREENE

Medical Director, TheraBody Monarch and The Madera Group

Dr. Greene is an Osteopathic Physician specializing in human performance, sports medicine, nutrition, and the most cutting edge recovery methods available in medicine. Dartmouth-Hitchcock Medical center in Lebanon, NH, and the world renowned Mayo Clinic in Rochester, MN.



DR. MARK JAMES THOMPSON

Biostatistician, Programmer and IP Economist*

Clinical Trial design and evaluation, HTA Modeling and Statistical Analysis. Formerly Lead Economist at Swiss Federal Institute of Intellectual Property.





WAKE

PRECISION MEDICINE AND PROTOCOLS

DR. RYAN GREENE


Wake Medical Team
Los Angeles, CA



WHY IS PRECISION MEDICINE IMPORTANT?

- Psychedelics are incredibly promising, but they are not a panacea.
- Not all treatments work. Response vs. Non-Response.
- We can solve for this utilizing Precision Medicine and using your genetics to understand if psychedelics will work for you or not.

Responsiveness to psilocybin-assisted therapy (depression)



Davis AK, Barrett FS, May DG, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2021;78(5):481–489.


HOW DOES IT WORK?

Medicine Today


1. Patient group is diagnosed with a condition.



2. Medicine developed for condition with efficacy.




It works great!



It worked well





Didn't work at all



Medicine Tomorrow



1. Precision medicine determines the best treatment path for you.



It works great!

2. Conditions are treated with medicine based on optimal genetic response.

OUR INDUSTRY LEADING PARTNERSHIP

Wake has signed a master collaboration agreement with the Lieber Institute for Brain Development Maltz Research Laboratories (LIBD). Together, LIBD and Wake aim to create a **cutting edge genetics-based research initiative that will act as a precision medicine and safety protocol for both dosing and efficacy.** LIBD is one of the only research institutions in the world focused specifically on understanding how genes and the environment influence the way our brains develop that lead to conditions such as schizophrenia, autism, depression, bipolar disorder and related developmental brain disorders.



DR. DANIEL R. WEINBERGER, M.D.

Director and CEO, Lieber Institute for Brain Development
Professor of Psychiatry, Neurology, Neuroscience and Genetic Medicine
Johns Hopkins University School of Medicine

TOGETHER WE ARE DEVELOPING SCREENING I.P.

Precision Medicine Screening aims to innovate safety protocols for modern psychedelic integration. The project will be a screening process which will be integrated with a one-of-a-kind AI-Reference library of human genetics.

PATH TO MARKET

Health Tech: Validated Genomic Risk Assessment
Approval Path: Medical Device / Health Tech Replacement
IP: Patent & Copyright Protection
Usage: Safety & Efficacy Screening for **ALL** Psychedelic Therapies
Objective Measures: Psynomic Risk Index Safety Measure



PSILOCYBIN RESEARCH AND PROTOCOL FOCUS

MACRODOSE

- Aim to discover the safety and efficacy of **macrodose psilocybin therapy for Traumatic Brain Injury (TBI)**
- Pilot project to determine efficacy of psilocybin for TBI.
- TBI has numerous side effects including susceptibility to depression, addiction, anxiety, memory loss and suicide ideation.

SAFETY


- Is real world use of psilocybin safe and effective?

MICRODOSE

- Aim to discover the safety and efficacy of **microdose psilocybin therapy for Anxiety and Depression.**
- Microdosing psilocybin represents the **largest and fastest growing use case of psilocybin**, and currently accessed entirely from mushrooms.
- Controlled research is needed to understand if microdosing psilocybin works.



PSILOCYBIN RESEARCH AND PROTOCOL FOCUS



PSIL428 MICRODOSE

Source: Psilocybin fungi
Approval Path: New drug application
IP: Proprietary formulation
Label Indication: Anxiety and depression
Objective Measures: Remote EEG, sEEG, Genetics
Location: Jamaica

Drug Registration
2021
Phase 2a & b
2022
Market Size¹
\$13.03B 2027



MACRODOSE

Source: Psilocybin fungi
Approval Path: New drug application
IP: Proprietary extraction and formulation
Label Indications: Traumatic brain injury
Objective Measures: EEG, sEEG, Genetics, Validated Index
Location: Canada, Jamaica

Drug Registration
2022
Phase 2a & b
2022/2023
Market Size²
\$76B USA



SAFETY

Source: Psilocybin fungi
Study Design: Observational Study
Objective Measures: Genomic, cardiovascular, adverse events
Location: Canada,



¹Fortune Business Insights

²Research and Markets, 2018

³CDC Severe TBI Economics



WAKE

PSILOCYBIN MEDICINE PRODUCTION

DR. AUDIA BARNETT

COO Wake Jamaica

Ph.D Molecular Chemistry



WHY NATURAL PSILOCYBIN MATTERS

Nearly all psilocybin consumed worldwide is consumed botanically from mushrooms. It has been used for thousands of years to heal minds, speak to deities, elevate consciousness and find deeper connection.

In 2022, the state of Oregon released draft rules banning synthetic psilocybin.

BOTANICAL

Our *Psilocybe Cubensis* mushrooms are fed a healthy diet of bamboo, lemongrass, coffee husks, rice, oats and other all natural substrate ingredients. We are focused on advancing this production method, free of contaminants like dung, commonly found in traditional psilocybin mushroom cultivation.



psilocybin

SYNTHETIC

Synthetic pharmaceutical psilocybin is commonly created using Benzene, a fossil fuel byproduct that may be found in glues, adhesives, cleaning products, tobacco smoke and gasoline. It is also commonly used to make medical products and pharmaceutical drugs.

ADVANCING PSILOCYBIN - ROADMAP

Wake is advancing product innovation from whole mushroom formulation to advanced pharmaceutical equivalents and creating multiple revenue opportunities.



BIOMASS

- Clinical grade whole mushroom biomass.
- Wholesale revenue opportunity for clinical research, laboratories, clinic operations, or patient access programs.




BOTANICAL DRUG

- PSIL428 full spectrum formulated microdose.
- Federally registered and approved.
- Local sales and global exports for medical, research and patient access programs.



EXTRACTION

- Isolation of psilocybin, psilocin and complementary tryptamine compounds.
- Purification, stabilization, formulation and delivery systems.
- Full spectrum extract sales.



DMF

- Drug Master File creation.
- Use of psilocybin in US for research.

PSILOCYBIN MUSHROOM PRODUCTION - JAMAICA

Built on empowerment and inclusion with female-led mycology team and decentralized farming initiatives. Wake Jamaica is a 50:50 joint venture with Pauline and Ronald Smith.



Wake Jamaica CEO *Pauline "Terri" Smith* and her team of growers which *supports women's entrepreneurial initiatives* in Jamaica.

REGISTRATION OF PSIL428


PSIL428 has been granted full drug registration and approval for experimental and clinical use.

PSIL428 is a 220mg (1mg Psilocybin) microdose product derived from naturally sourced psilocybin which we intend to be made available for local markets and export.

PSIL428 is the first legal psilocybin mushroom based Rx drug in the world.



Pharmacy sales in Jamaica and export to authorized jurisdictions.



Use in clinical trials, pilot projects and patient programs.



Sales to other clinic networks.



INTERNATIONAL MUSHROOM EXPORT UNDERWAY

Wake has completed the first Drug Enforcement Administration (DEA) approved importation into the United States. Wake is now in progress on multiple supply chain opportunities.




United States
(Complete)



- Product Analysis
- Stability
- Extraction
- Formulation

Supply Chain Opportunities



Canada
COMPLETE



Israel
2022



British Virgin Islands
2022



Australia
2022

ADVANCED DRUG FORMULATION FOR PSILOCYBIN

Wake is focused on creating innovative drug IP and formulations using naturally derived psilocybin and critical associated compounds through our laboratory relationships and partners.



- The Lab Partners are health Canada Drug Establishment Licensed. FDA certified and registered.
- Fully licensed for psilocybin, psilocin, baeocystin, norbaeocystin, and other critical compounds for naturally derived psilocybin mushrooms.
- Innovation in propagation, cultivation, extraction, analytics, formulation, stability testing, sales and drug approval paths
- Importation of Wake psilocybin biomass from Jamaica in progress.





WAKE

CLINICAL VALIDATION AND INTEGRATION

JESS

Artist

Postpartum Depression

Venice, California

Wake Clinic Patient 2020






WAKE

In March 2022, groups of professional athletes and combat veterans will be the first to attend a groundbreaking psilocybin therapy at the Wake Clinical Research Retreat.

This ongoing clinic will be instrumental in capturing the critical response data to validate our precision medicine approach.





EBEN BRITTON


NFL Alumni
Chicago Bears

THE WAKE WELLNESS PLATFORM CAPTURES IT ALL

Through Wake's partnership with the AdvancedCare HIPAA compliant software, Wake has been building from the ground up an integrated research and treatment platform aimed at delivering psilocybin and integration therapies alongside vitals, brain monitoring and virtual clinical tools.



THE EXPERIENCE



TESTIMONIALS




MARK LONG
RCMP Veteran and First Responder

"After 18 years of policing, 2 hospitalizations, and a diagnosis of complex PTSD I felt lost and confused for years and struggled to reconnect and reintegrate back into regular society. The love, support, and understanding I was shown during my week at Wake Clinic was nothing short of a miracle. While so many Therapist and Doctors I have dealt with were quick to prescribe pharmaceuticals to fix the trauma I've experienced, it was my spirit and the abandonment of myself that was crushing me daily. Wake Clinic allowed me to find purpose, meaning in my life again and made me finally see clearly. My heart and not my brain that needed healing. I feel alive, happy, and awake again."



JESSICA JAMES
Artist and Stay at Home Mom

"My experience with Wake Clinics was truly transformative. The psilocybin assisted sound-bath and integration therapy allowed me to dive deep into my subconscious and invite my pain and trauma to the table for a new conversation. Turning my pain into fuel rather than being a heavy weight to be ashamed of."



RILEY COTE
NHL Alumni

"The Wake Clinic was a transformational experience with a great community of people. The safe and comfortable environment allowed me to do the inner work I needed to progress with my life as a father, husband and business leader."




ALEX VINCENT
US Marine Veteran

"The Wake Clinic provided me a sense of community and intimacy that I, like so many others, have been needing. It has allowed me to be more vulnerable and expressive with others, while also realizing the love and potential I have inside."



THANK YOU



Watch

[Ex NHL-er Riley Cote on Using Psychedelic Mushrooms for Brain Trauma with Wake](#)

WARREN NEEDLER
warren@wake.net

NICK MURRAY
nmurray@wake.net